Corporate & Investor Presentation
Study demonstrates the effectiveness of CPAP therapy and
quality of life improvements for those with mild obstructive sleep apnea
MERGE trial: clinical effectiveness of CPAP treatment in patients with mild obstructive sleep apnea
Demonstrated improvement in
56.
●
CPAP
-Standard care
Quality of Life (SF-36 vitality scale)
Treatment effect 7-5 (95% CI 5-3-9-6); p<0-0001
54-
for CPAP patients vs. standard
care
Symptomatic benefits:
•
Reductions in sleepiness
52
Mean vitality score (95% CI)
46-
48-
g
Improvements in fatigue and
depression
Compelling evidence supports the need
and benefits of treating mild OSA
Combined with recently published global prevalence
research, 936M patients worldwide can benefit from
PAP treatment
44
42-
T
40
Baseline
Month 3
Visit
Change in SF-36 Vitality Scale
in Patients with Mild OSA per AASM 2012
Wimms et al. Lancet Respir Med 2019
47 2021 ResMed | Corporate & Investor Presentation - updated 28JAN21
MMERGE
Blackpool
Liverpool
Dundee
Cambridge
Oxford
Taunton
Plymouth
UK Respiratory Sleep
Research Network
Newcastle
Stevenage
London (G&ST)
London (RB&HT)
ResMedView entire presentation